ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Chroma Medicine, an epigenetic editing company, has raised $135 million in series B financing from investors including GV, formerly known as Google Ventures, and Arch Venture Partners. Chroma will use the funding to advance into the clinic its single-dose therapeutics platform, which can regulate gene expression durably without permanently altering the genome. The company’s technology relies on transient effector molecules that can methylate or demethylate genes to switch them off or on.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X